| Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials P Fusar-Poli, E Papanastasiou, D Stahl, M Rocchetti, W Carpenter, ... Schizophrenia bulletin 41 (4), 892-899, 2015 | 686 | 2015 |
| Disorder, not just state of risk: meta-analysis of functioning and quality of life in people at high risk of psychosis P Fusar-Poli, M Rocchetti, A Sardella, A Avila, M Brandizzi, E Caverzasi, ... The British Journal of Psychiatry 207 (3), 198-206, 2015 | 298 | 2015 |
| Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis V Tourjman, E Kouassi, ME Koue, M Rocchetti, S Fortin-Fournier, ... Schizophrenia research 151 (1-3), 43-47, 2013 | 253 | 2013 |
| Prevalence of self-reported childhood abuse in psychosis: a meta-analysis of retrospective studies I Bonoldi, E Simeone, M Rocchetti, L Codjoe, G Rossi, F Gambi, U Balottin, ... Psychiatry research 210 (1), 8-15, 2013 | 239 | 2013 |
| Complementary and alternative therapies for autism spectrum disorder N Brondino, L Fusar-Poli, M Rocchetti, U Provenzani, F Barale, P Politi Evidence-Based Complementary and Alternative Medicine 2015, 2015 | 181 | 2015 |
| Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation A Schmidt, M Cappucciati, J Radua, G Rutigliano, M Rocchetti, ... Schizophrenia bulletin 43 (2), 375-388, 2017 | 160 | 2017 |
| Why are help-seeking subjects at ultra-high risk for psychosis help-seeking? I Falkenberg, L Valmaggia, M Byrnes, M Frascarelli, C Jones, M Rocchetti, ... Psychiatry research 228 (3), 808-815, 2015 | 154 | 2015 |
| Peripheral oxytocin and vasopressin: biomarkers of psychiatric disorders? A comprehensive systematic review and preliminary meta-analysis G Rutigliano, M Rocchetti, Y Paloyelis, J Gilleen, A Sardella, ... Psychiatry Research 241, 207-220, 2016 | 149 | 2016 |
| Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis G Rutigliano, L Valmaggia, P Landi, M Frascarelli, M Cappucciati, V Sear, ... Journal of affective disorders 203, 101-110, 2016 | 148 | 2016 |
| Is cannabis neurotoxic for the healthy brain? A meta‐analytical review of structural brain alterations in non‐psychotic users M Rocchetti, A Crescini, S Borgwardt, E Caverzasi, P Politi, Z Atakan, ... Psychiatry and clinical neurosciences 67 (7), 483-492, 2013 | 141 | 2013 |
| Towards a standard psychometric diagnostic interview for subjects at ultra high risk of psychosis: CAARMS versus SIPS P Fusar-Poli, M Cappucciati, G Rutigliano, TY Lee, Q Beverly, I Bonoldi, ... Psychiatry journal 2016, 2016 | 129 | 2016 |
| The role of intranasal oxytocin in anxiety and depressive disorders: A systematic review of randomized controlled trials F De Cagna, L Fusar-Poli, S Damiani, M Rocchetti, G Giovanna, A Mori, ... Clinical Psychopharmacology and Neuroscience 17 (1), 1, 2019 | 107 | 2019 |
| Adult Autism Subthreshold Spectrum (AdAS Spectrum): Validation of a questionnaire investigating subthreshold autism spectrum L Dell'Osso, C Gesi, E Massimetti, IM Cremone, M Barbuti, G Maccariello, ... Comprehensive psychiatry 73, 61-83, 2017 | 105 | 2017 |
| Diagnosing ASD in adults without ID: accuracy of the ADOS-2 and the ADI-R L Fusar-Poli, N Brondino, M Rocchetti, C Panisi, U Provenzani, S Damiani, ... Journal of autism and developmental disorders 47, 3370-3379, 2017 | 97 | 2017 |
| A systematic review of cognitive effects of exercise in depression N Brondino, M Rocchetti, L Fusar‐Poli, E Codrons, L Correale, M Vandoni, ... Acta Psychiatrica Scandinavica 135 (4), 285-295, 2017 | 90 | 2017 |
| Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study P Fusar-Poli, M Frascarelli, L Valmaggia, M Byrne, D Stahl, M Rocchetti, ... Psychological medicine 45 (6), 1327-1339, 2015 | 87 | 2015 |
| Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-aminoethoxy) imino) androstane-6, 17-dione hydrochloride (PST2744) R Micheletti, GG Mattera, M Rocchetti, A Schiavone, MF Loi, A Zaza, ... Journal of pharmacology and experimental therapeutics 303 (2), 592-600, 2002 | 72 | 2002 |
| What are we targeting when we treat autism spectrum disorder? A systematic review of 406 clinical trials U Provenzani, L Fusar-Poli, N Brondino, S Damiani, M Vercesi, N Meyer, ... Autism 24 (2), 274-284, 2020 | 64 | 2020 |
| Neurofunctional maps of the ‘maternal brain’and the effects of oxytocin: A multimodal voxel‐based meta‐analysis M Rocchetti, J Radua, Y Paloyelis, LA Xenaki, M Frascarelli, E Caverzasi, ... Psychiatry and clinical neurosciences 68 (10), 733-751, 2014 | 58 | 2014 |
| Rate dependency of β‐adrenergic modulation of repolarizing currents in the guinea‐pig ventricle M Rocchetti, V Freli, V Perego, C Altomare, G Mostacciuolo, A Zaza The Journal of physiology 574 (1), 183-193, 2006 | 49 | 2006 |
Fusar-Poli PaoloPrimary: King's College London, UK; Secondary: University of Pavia, ItalyVerified email at kcl.ac.uk
